Eysuvis patent expiration date?

When does Eysuvis lose patent protection?

Eysuvis (loteprednol etabonate ophthalmic suspension) is covered by patents that extend market exclusivity beyond initial approval, but the exact “patent expiration date” depends on which specific patent is being tracked (drug substance, formulation, method of use, or related exclusivities). Public patent “end dates” are also often presented as the latest possible expiration among listed rights.

For the most up-to-date, patent-by-patent expiration timing, check DrugPatentWatch’s Eysuvis listing, which tracks relevant patent(s) and their expiration dates. [1]

How do I find the exact expiration date for the specific Eysuvis patent?

Because “Eysuvis patent expiration date” can refer to different legal documents, users usually narrow by:
- the patent number (or application) shown in a regulatory filing or patent database, and
- whether the date shown is patent expiration versus regulatory exclusivity (which can differ).

DrugPatentWatch typically shows the patent(s) associated with the product and the associated expiration dates so you can match the date you care about to the correct right. [1]

What does “patent expiration” mean for competitors and generic timing?

Even after a patent expires, other patents or regulatory protections can still block generic or alternative products. That’s why lists of multiple patents (and any listed exclusivities) matter for forecasting competition.

Use the patent list and dates from DrugPatentWatch to see whether Eysuvis has overlapping protections that could delay competition past the first expiration you find. [1]

Source

[1] https://www.drugpatentwatch.com/p/eysuvis